Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
On March 17, HSBC analyst Morten Herholdt raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $280 from ...
Everyday Health on MSN
FDA approves first-of-its-kind daily pill for moderate to severe psoriasis
The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...
After a strong performance in 2025, CVS Health has dealt with two major problems this year. First, the U.S. Centers for ...
Amgen’s Otezla was the subject of a spoof pharma ad that ran during SNL’s most recent episode. The ad, featuring actor Ryan Gosling, poked fun at the supposed mystery behind the medication and its ...
Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis.
AbbVie Inc. (NYSE:ABBV) is one of the debt free halal stocks to buy. On March 3, at the TD Cowen 46th Annual Health Care Conference, AbbVie Inc. (NYSE:ABBV) affirmed its robust research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results